Targeting of Protein’s Messenger RNA for Viral Replication, Assembly and Release in SARS-CoV-2 Using Whole Genomic Data From South Africa: Therapeutic Potentials of Cannabis Sativa L

Ochuko L. Erukainure 1, Motlalepula G. Matsabisa 1*, Aliyu Muhammad 2, Musa M. Abashi 2, James F. Amaku 3, Sanusi B. Katsayal 2 and Adeline Lum Nde 1

1Department of Pharmacology, School of Clinical Medicine, Faculty of Health Sciences, University of the Free State, Bloemfontein, South Africa, 2Department of Biochemistry, Faculty of Life Sciences, Ahmadu Bello University, Zaria, Nigeria, 3Department of Chemistry, Michael Okpara University of Agriculture, Umudike, Nigeria

The possible evolutionary trend of COVID-19 in South Africa was investigated by comparing the genome of SARS-CoV-2 isolated from a patient in KwaZulu-Natal, South Africa with those isolated from China, Spain, Italy, and United States, as well as the genomes of Bat SARS CoV, Middle East Respiratory Syndrome Coronavirus (MERS-CoV), Mouse Hepatitis Virus (MHV), and Infectious Bronchitis Virus (IBV). Phylogenetic analysis revealed a strong homology (96%) between the genomes of SARS-CoV-2 isolated from KwaZulu-Natal, South Africa and those isolated from the study countries as well as those isolated from bat SARS CoV, MERS-CoV, MHV and IBV. The ability of phytocannabinoids from Cannabis sativa infusion to interact with gene segments (mRNAs) coding for proteins implicated in viral replication, assembly and release were also investigated using computational tools. Hot water infusion of C. sativa leaves was freeze-dried and subjected to Gas Chromatography-Mass Spectroscopy analysis which revealed the presence of tetrahydrocannabivarin, cannabispiran, cannabidiol tetrahydrocannabinol, cannabigerol, and cannabinol. Molecular docking analysis revealed strong binding affinities and interactions between the phytocannabinoids and codon mRNAs for ORF1ab, Surface glycoprotein, Envelope protein and Nucleocapsid phosphoprotein from SARS-CoV-2 whole genome which may be due to chemico-biological interactions as a result of nucleophilic/electrophilic attacks between viral nucleotides and cannabinoids. These results depict the spread of SARS-CoV-2 is intercontinental and might have evolved from other coronaviruses. The results also portray the phytocannabinoids of C. sativa infusion as potential therapies against COVID-19 as depicted by their ability to molecularly interact with codon mRNAs of proteins implicated in the replication, translation, assembly, and release of SARS-CoV-2. However, further studies are needed to verify these activities in pre-clinical and clinical studies.

Keywords: Cannabis sativa, COVID-19, SARS-CoV-2, phytocannabinoids, South Africa
INTRODUCTION

The outbreak of the corona virus disease 2019 (COVID-19) pandemic has led to an unprecedented pressure on the global health sector, with the sub-Saharan African countries as well as other developing countries being among the most hit (Chen et al., 2020; Willan et al., 2020). The disease which originated from Wuhan China in December 2019 as cluster crises of pneumonia, is caused by the novel β-coronavirus, Severe Acute Respiratory Syndrome Coronavirus 2 popularly regarded as SARS-CoV-2.

Italy, the United Kingdom and Spain were the epicenters for the pandemic in Europe, United States for North America, Brazil for South America, and South Africa for Africa. Although the cases of COVID-19 and mortality rate is lower in African countries compared to other continents, the pandemic has caused a lot of pressure on the poor health systems and economies of these countries which were already burdened with existing non-communicable diseases particularly malaria, AIDS and tuberculosis (Hogan et al., 2020; Sands, 2020; Sherrard-Smith et al., 2020). These setbacks coupled with an uncontrolled growing population exacerbates the continent’s vulnerability to the pandemic with major consequences. Egypt was the first to announce a case in the continent on February 14, 2020, this was followed by Nigeria on February 27, 2020, while South Africa announced her index case on March 5, 2020 (Lone and Ahmad, 2020; Zhao et al., 2020). These figures have so far grown to over 6 digits with South Africa presently having the highest cases. It is pertinent to mention that the virus was brought into the continent by travelers from Europe and has so far led to community spread.

The absence of a substantial standard protocol treatment and vaccine for the disease have led to continuous efforts by scientists and policy makers to curb the disease spread through mainly non-pharmaceutical interventions. These efforts include public sensitization on the virus and the disease, testing, patient isolation and contact tracing, as well as implementation of government policing such as national lockdown, social and physical distancing, mandatory public use of face mask, and constant washing of hands (Müttjä and Clotet, 2020). Despite South Africa passing some of the world’s stringent lockdown rules to curb the transmission of the virus, it has experienced an exacerbated growth in the number of cases which have caused tremendous strain on her health care system and economy. This has led to the search of novel and cheaper alternatives for the treatment of the diseases, with much attention given to indigenous medicinal plants. This has also led to the African stance through the WHO afro, Africa-CDC and the AU Commission in setting up an expert committee on traditional medicines for COVID-19 which aims at strengthening African countries by finding traditional medicines for the disease.

Several studies have reported the potentials of medicinal plants in the treatment and management of COVID-19 and its complications (Benarba and Pandiella, 2020; Erukainure et al., 2020; Vellingiri et al., 2020). These therapeutic properties have been attributed to the phytochemical constituents of the plants. Amongst these plants is Cannabis sativa.

Cannabis sativa is a member of the Cannabis genus and the Cannabaceae family. It is an annual herbaceous plant commonly known as weed, marijuana, Indian hemp, weed and dagga in different parts of the world. Its utilization cuts across religious and recreational purposes, as well as traditional medicine and food (Kuddus et al., 2013; Bonini et al., 2018). The plant is now the most reported for its pharmaceutical medical uses and it is regarded as a global specie as it is widely distributed across the world (UNODC, 2012). Although its utilization is under strict rules in most countries, Cannabis has over the years been reported to be effective in the treatment and management of several ailments such as diabetes mellitus (Ren et al., 2016), different cancer types (Guzman, 2003), insomnia (Ramar et al., 2018), epilepsy (Fusar-Poli et al., 2009), severe pains (Whiting et al., 2015) and neurodegeneration (Aso and Ferrer, 2016). These medicinal properties have been attributed to the phytochemical constituents of Cannabis, particularly the phytocannabinoids. Cannabidiol (CBD), tetrahydrocannabinol (THC) and cannabinoil (CBN) constitute the predominant phytocannabinoids in Cannabis (Andre et al., 2016), and have been studied widely for their medicinal applications.

Recently, Cannabis has been gaining interests as a possible therapy for the treatment of COVID-19 and its complications (Byrareddy and Mohan, 2020; Mabou Tagné et al., 2020). This has been attributed to the antiviral activities of its phytocannabinoids such as CBD against hepatitis C and Kaposi sarcoma (Mabou Tagné et al., 2020), as well as its potent anti-inflammatory properties as depicted by its ability to suppress the production of TNF-α, IFN-α, IL-2, IL-6, IL-1 and IFN-γ in the progression of COVID-19 induced by SARS-CoV-2 via the cytokine release syndrome (CNS) (Mehta et al., 2020; Nichols and Kaplan, 2020). These proinflammatory cytokines have been implicated in the pathogenesis and progression of COVID-19 induced by SARS-CoV-2 via the cytokine release syndrome (CNS) (Mehta et al., 2020; Nichols and Kaplan, 2020; Shi et al., 2020) commonly regarded as the cytokine storm. Therefore, studying the potentials of Cannabis and its phytocannabinoids as a possible therapy in the treatment and management of COVID-19 will contribute to the curbing of the disease.

This study aimed at decoding the possible evolutionary trend of COVID-19 in South Africa by comparing the genome of SARS-CoV-2 isolated from KwaZulu-Natal, South Africa with those isolated from China, Spain, Italy and United States, as well as the genomes of Bat SARS CoV, Bat SARS CoV-2 (Rome, Italy), Bat SARS CoV-2 (New York, United States), Bat SARS CoV Rs672/2006, MERS-CoV, MHV.

MATERIALS AND METHODS

Viral Genome Sequences

Different complete genome sequences (MT324062, MT291830, MT198652, MT077125, MT371047, F1588686.1, M923481, MF618252.1, and NC_001451.1) of SARS-CoV-2 (KwaZulu-Natal, South Africa), SARS-CoV-2 (Wuhan, China), SARS-CoV-2 (Valencia, Spain), SARS-CoV-2 (Rome, Italy), SARS-CoV-2 (New York, United States), Bat SARS CoV Rs672/2006, MERS-CoV, MHV.
and IBV respectively (Table 1), were retrieved from the National Center for Biotechnology Information (NCBI) database and thereafter subjected to alignment using CLUSTALW X Software, version 10.1.8 (Kumar et al., 2018) (Supplementary Figure S1). The aligned sequences were then used to plot phylogenetic tree.

Phylogenetic Analysis; Evolutionary Relationships of Taxa

The evolutionary history was inferred using the UPGMA method (Sneath and Sokal, 1973). The optimal tree with the sum of branch length = 1.90049281 is shown. The tree was drawn to scale, with branch lengths in the same units as those of the evolutionary distances used to infer the phylogenetic tree. The evolutionary distances were computed using the Maximum Composite Likelihood method (Tamura et al., 2004) and are in the units of the number of base substitutions per site. This analysis involved 9 nucleotide sequences of the aforementioned viruses. All ambiguous positions were removed for each sequence pair (pairwise deletion option). There was a total of 31,304 positions in the final dataset. Evolutionary analyses were conducted using MEGA X (Kumar et al., 2018).

Plant Material

The use of *C. sativa* was approved by the South African Health Products Regulatory Authority to conduct, collect, possess, transport and store cannabis plant, plant parts and products for research purposes (Permit No. POS 248/2019/2020; permit issued to the University of Free State).

*Cannabis sativa* leaves were collected from Mohale’s Hoek District, Lesotho (GPS coordinates: 30.333776°S and 27.651201°E) under the permit (Permit #: 01/LS/2019/10–02–01). The leaves were deposited with the voucher number: BLFU MGM 0018 following its identification and authentication by the Geo Potts Herbarium at the University of the Free State, Bloemfontein 9300, South Africa.

Infusion of *C. sativa* Leaves

The leaves were air-dried and blended to smooth powder. About 30 g of the powdered samples were infused in boiled water and allowed to extract for 2 h. The infusion was decanted into plastic bowls and allowed to freeze at −80°C before freeze-drying to yield about 9 g of concentrated infusion. The sample was stored in glass vials and stored at 2°C until further analysis.

Gas Chromatography-Mass Spectrometric Analysis

The concentrated sample was subjected to GC-MS analysis in order to identify the compounds. This was carried out with an Agilent technologies 6890 Series GC coupled with (an Agilent) 5973 Mass Selective detector, which is driven by Agilent Chemstation software. The operating parameters were:

- Column: HP-5MS capillary column (30 × 0.25 mm ID, 0.25 μm film thickness, 5% phenylmethylsiloxane); Carrier gas: ultra-pure helium; Gas flow rate: 1.0 ml/min at a linear velocity of 37 cm/s; Programmed oven temperature: 280°C (at the rate of 10°C/min with a hold time of 3 min); Injector temperature: 250°C; Ion source temperature: 230°C; Quadrupole temperature: 150°C; Electron ionization mode: 70 eV; Electron multiplier voltage: 1859 V; Solvent delay: 4 min; Scan range: 50–70 amu.

An inbuilt NIST data library was used in identifying the compounds via comparison of retention time and mass spectral data. The GC-MS spectra is shown in Supplementary Figure S2.

SARS-CoV-2 Protein mRNA Sequence

SARS-CoV-2 (KwaZulu-Natal, South Africa) whole genome mRNA sequence was obtained from PubMed database from corona virus whole genome (MT324062.1). Gene segment coding for ORF1ab, Surface glycoprotein, Envelope protein and Nucleocapsid phosphoprotein were identified. Possible initiation and termination sequence of the gene were selected based on the identification of regions carrying initiation and termination codons as shown in Table 2. About 45–50 nucleotide sequence from both initiation and termination codons were converted into 3D single mRNA strand using Discovery studio (v19.1.0.18287) and saved as protein data bank file (Biovia, 2015). The structures were prepared by removing all solvent molecules and optimized to simulate physiological conditions using Chimera v 1.1. Polar hydrogens were added, and partial charges were assigned to the standard residue using Gasteiger partial charge.

Molecular Docking

The chemical structure of tetrahydrocannabinvarin, cannabispiran, cannabidiol tetrahydrocannabinol, cannabigerol, cannabinoil, hydroxycellorquione and remdesivir were retrieved from PubChem online webserver. Gaussian 09 equipped with GaussianView 5.0 was used to optimize the chemical structures (ligands). The optimize ligands were then converted to PDB files using UCSF Chimera tool. The crystal structure of the mRNA (receptors) was built from selected sequence of initiation and termination sites obtained from SARS-COV 2 proteins by making use of UCSF Chimera tool. Hydrogen and Gasteiger partial charges were added to the receptor using the UCSF Chimera tool. Molecular docking simulation was performed on a nucleic acid docking server (HNADOCK). Finally, the ligand-mRNA interaction was assessed using Maestro 11.5 a Schrodinger 2018–1 suite package.

| TABLE 1 | Viral genome codes used for the present study. |
|---------|-----------------------------------------------|
| NCBI Genome Codes | Virus | Country Source |
| MT324062 | SARS-CoV-2 | South Africa (KwaZulu-Natal) |
| MT291830 | SARS-CoV-2 | China (Wuhan) |
| MT198652 | SARS-CoV-2 | Spain (Valencia) |
| MT077125 | SARS-CoV-2 | Italy (Rome) |
| MT371047 | SARS-CoV-2 | United States (NY) |
| FJS868681.1 | Bat SARS CoV Res72/2006 | |
| MG923481.1 | MERS-CoV | |
| MF618252.1 | MHV | |
| NC_001451.1 | IBV | |
Hydroxychloroquine and remdesivir were chosen as the control antiviral drugs owing to previous reports on their use in the treatment and management of COVID-19 (Al-Tannak et al., 2020; Wang et al., 2020).

RESULTS

Phylogenetic Analysis
The South African SARS-CoV-2 isolate evidently clustered with other SARS-CoV-2 isolates from other countries (China, Italy, United States and Spain) with 96% homology as shown in Figure 1. Interestingly, it also showed 93% homology with the isolate from Bat. This was followed by 92 and 94% homology with MERS-CoV isolate and MHV/IBV, respectively.

Gas Chromatography-Mass Spectrometric Analysis
As depicted in Figure 2 and Table 3, GC-MS analysis of the infusion revealed the presence of tetrahydrocannabivarin, cannabispiran, CBD, THC, cannabigerol and cannabinol. The highest concentration were THC and cannabinol, with 73.84 and 21.74% abundance, respectively as shown in Table 3.

Molecular Docking
The structure of the compounds and their best docked conformations within the binding site of the selected receptors are shown in Figures 3–8. These favorable interactions between the molecules are depicted by the binding energy as indicated in Table 4. All the compounds bounded to the target sequence reasonably with similar binding pattern. The bindings were seen within the beginning, middle and end of the initiation and termination codons of the various viral proteins respectively. These interactions include both polar and nonpolar through hydrogen, hydrophobic and other non-conventional interactions.

DISCUSSION
Since its outbreak in Wuhan China, SARS-CoV-2 has spread across the globe leading to the COVID-19 pandemic. The spread of the
FIGURE 2 | GC-MS identified compounds from C. sativa infusion.

TABLE 3 | GC-MS identified compounds in C. sativa infusion.

| Compounds               | % Abundance | Molecular formula | Molecular weight |
|-------------------------|-------------|-------------------|------------------|
| Tetrahydrocannabivarin | 1.66        | C_{12}H_{20}O_{2}  | 286.4            |
| Cannabispiran           | 0.07        | C_{12}H_{18}O_{3}  | 246.3            |
| Cannabidiol             | 1.67        | C_{21}H_{30}O_{2}  | 314.5            |
| Tetrahydrocannabinol    | 73.84       | C_{21}H_{26}O_{2}  | 314.5            |
| Cannabigerol            | 1.03        | C_{21}H_{32}O_{2}  | 316.5            |
| Cannabinol              | 21.74       | C_{21}H_{28}O_{2}  | 310.4            |

FIGURE 3 | 3D Interaction of Remdesivir with Initiation and Termination Sequence of the Viral Proteins. A = Nucleocapsid Phosphoprotein Translation Initiation Site; B = Envelope Protein Translation Initiation Site; C = Envelope Protein Translation Termination Site; D = Nucleocapsid Phosphoprotein Translation Termination Site; E = ORF1ab Translation Initiation Site; F = ORF1ab Translation Termination Site; G = Surface Glycoprotein Translation Termination Site; H = Surface Glycoprotein Translation Initiation Site.
The study decoded the origin of the virus in South Africa by comparing the genome of SARS-CoV-2 isolated from KwaZulu-Natal, South Africa with those of countries with reported high cases (Table 1). The 96% homology with genomes from China, Spain, Italy and United States suggests SARS-CoV-2 in South Africa originated from outside the continent and corroborates reports that her index COVID-19 case was a male citizen who tested positive to the virus after a trip to Italy (SAG, 2020). This also corroborates the global spread of the virus and the disease (Lee, 2020; Macintyre, 2020). Furthermore, the 93% homology of the genome of the South African isolate with bat SARS CoVs, as well as the 92 and 94% homology with MERS-COV and MHV/IBV isolates, respectively insinuates an evolutionary conservation among the whole genomes of the studied coronaviruses. These evolutionary trends corroborate reports that suggest coronaviruses are of bat origin (Liu et al., 2020; York, 2020; Zhou et al., 2020).
Coronaviruses are enveloped viruses with a single strand, positive-sense RNA genome of 27–32 kb in length (Liu et al., 2007). Several studies have reported more than 100 full-length or partial genomic sequences for SARS-CoV-2 (Wang et al., 2020). The genome contains about six to nine sorts of mRNA, comprising the genome-length mRNA and five to eight sub-genomic mRNA which code for structural protein and many other for non-structural proteins (Liu et al., 2007). In an infected cell, coronaviruses induce the formation of double-membrane vesicles and convoluted membranes that harbor the nonstructural proteins (Verheije et al., 2010). The structural proteins include transmembrane spike glycoprotein,
leading to the formation of virus-like particles and the glycoproteins induce virion assembly and morphogenesis function as an RNA chaperone. Envelope and surface nucleocapsid that is uniphosphoprotein packages the viral genome to form the helical and synthesis of the subgenomic RNAs, while nucleocapsid membrane endocytosis. ORF1 stimulates the virus replication mechanism of SARS-CoV-2 starts with its transmembrane synthesis and replication (Tsai et al., 2020). The entry and ORF10 which contains information for genome RNA nonstructural includes ORF1ab, ORF3, ORF6, ORF7a, ORF8, release of the virions by exocytosis (Ho et al., 2004; Zúñiga − SGIS − SGST Frontiers in Pharmacology | www.frontiersin.org September 2021 | Volume 12 | Article 736511 8

nucleocapsid phosphoprotein, envelope, and surface glycoproteins (Baudoux et al., 1998), whereas the nonstructural includes ORF1ab, ORF3, ORF6, ORF7a, ORF8, and ORF10 which contains information for genome RNA synthesis and replication (Tsai et al., 2020). The entry mechanism of SARS-CoV-2 starts with its transmembrane spike glycoprotein attachment to host cell membrane receptor (angiotensin-converting enzyme 2) and induce its entry through membrane endocytosis. ORF1 stimulates the virus replication and synthesis of the subgenomic RNAs, while nucleocapsid phosphoprotein packages the viral genome to form the helical nucleocapsid that is unified into the budding particle and can also function as an RNA chaperone. Envelope and surface glycoproteins induce virion assembly and morphogenesis leading to the formation of virus-like particles and the final release of the virions by exocytosis (Ho et al., 2004; Zúñiga et al., 2007; Andersen et al., 2020). Any attempt to interfere with the expression of one of these proteins could be tantamount to disrupting the overall SARS-COV-2 transmission cycle. Therefore, targeting these structural and nonstructural protein components especially at translational level of mRNAs being converted to proteins, could serve as a viable therapeutic strategy against SARS-COV-2. This is corroborated by studies which reported ORF1ab, surface glycoprotein, nucleocapsid phosphoprotein, envelope, membrane, spike protein, protease, hemagglutinin esterase and helicase as possible therapeutic target for coronaviruses including SARS-CoV-2 (Mbride et al., 2014; Bhatia et al., 2020). The strong binding affinities of the identified compounds from C. sativa (Figure 2 and Table 3) with both the initiation and termination codons of ORF1ab, Surface glycoprotein, Envelope protein and Nucleocapsid phosphoprotein mRNAs from the whole genome of SARS-CoV-2 isolated from KwaZulu-Natal, South Africa (Figures 3–8) therefore, portray their high potential as possible therapy

![Diagram](image-url)
for treatment of COVID-19 and its complication by curbing the replication, translation, assembly, and release of the virus. The mechanism of these strong binding affinities of the identified compounds from *C. sativa* against the identified mRNA initiation and termination codons could be due some chemico-biological interactions based on the chemistry of the said bioactive compounds versus that of nucleotides. Literally, the constituents of mRNA include adenine, guanine, cytosine, uracil and a phosphate terminal (Elliott and Ladomery, 2017). Meanwhile, these chemical compounds are classified as purine and pyrimidines and are known to constitute basic functional group (amine and carboxyl) with the capacity to undergo nucleophilic or electrophilic reactions (Ulbricht, 2016). In the biological system, natural product dissociates, hence, the tendency to interact with purines and pyrimidines via electrostatic, hydrophobic, intermolecular force or covalent bond is certain. GC-MS analysis of *Cannabis sativa* extract revealed the presence of tetrahydrocannabivarin, cannabispian, cannabidiol tetrahydrocannabinol, cannabigerol, and cannabinol. These compounds contain free hydroxyl and aromatic rings which confers on them the ease to interact with the purines, pyrimidines, or phosphate terminal of SARS-CoV-2 genome mRNA sequence via hydrogen bonding or intermolecular interaction. Hydrogen bond formation between the oxygen at carbon 2 of the purines on the genome of SARS-CoV-2 mRNA may be responsible for its interaction with natural product. On the other hand, the free amine attached to carbon 2 and 6 of guanine and adenine respectively may account for the mechanism of interactions (electrostatic) between pyrimidines and the natural product obtained from *Cannabis sativa* extract. Similarly, the phosphate terminal of the SARS-CoV-2 mRNA could electrostatically interact with the polar region of electron deficient natural product that may have dissociated with the biochemical environment. Hence, at a favourable pH within the biochemical system, natural product obtained from *Cannabis sativa* extract can dissociate to impart a possible therapeutic function against COVID-19. Furthermore, flavonoid-based molecules from *C. sativa* have also been shown to bind with high affinity to the spike protein, helicase, and protease sites on the ACE2 receptor used by the coronavirus 2 to infect cells and cause COVID-19 (Attia et al., 2020; Khanna et al., 2020).

Interestingly, the viral proteins have also been implicated in manipulating the host’s innate immune system (Alexander et al., 2019). Conversely, *C. sativa* and its phytocannabinoids have been proposed as a possible natural products for the treatment of COVID-19 (El Biali et al., 2020; Mckernan et al., 2020). This is also coupled with their reported potent anti-inflammatory activities especially CBD, tetrahydrocannabivarin and THC (Bolognini et al., 2010; Anil et al., 2020; Nichols and Kaplan, 2020) as the pathogenesis and progression of the virus have been linked to excessive production of pro-inflammatory cytokines often termed as cytokine storm syndrome leading to suppression of the immune system (Ragab et al., 2020; Vaninov, 2020).

These results further indicate that phytochemicals from *C. sativa* can respond to the COVID-19 at different levels of its mRNAs and different mechanisms. They corroborate previous studies that tentatively indicated that CBD and THC may be beneficial in the treatment of patients whose bodies’ inflammatory response has become pathogenic and therefore respond to the cytokine storm (Nagarkatti et al., 2009; Onaivi and Sharma, 2020; Rossi et al., 2020). Much research in this field has focused on the ability of cannabinoids and terpenes to lower the immune system’s response without suppressing.

**CONCLUSION**

Taken together, the results from this study indicates a homology between the genome of SARS-CoV-2 isolated from KwaZulu-Natal, South Africa and those isolated from Europe, Asia and North America, as well as those isolated from bat SARS COV, MERS-CoV, MHV and IBV. Thus, depicting the spread of the virus is intercontinental and might have evolved from other coronaviruses. The results also indicate the phytocannabinoids of *C. sativa* infusion as potential therapies against COVID-19 as depicted by their ability to molecularly interact with codon mRNAs of proteins implicated in the replication, translation, assembly, and release of SARS-CoV-2. However, further studies are needed to verify these activities pre-clinically and clinically. It is also recommended that LC-MS analysis should be carried out on the infusion to further identify its polar constituents.

**DATA AVAILABILITY STATEMENT**

The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding author.

**AUTHOR CONTRIBUTIONS**

Concepts: OE and MM; Research Design: OE, AM, and JA; Execution and Interpretation of Results: AM, MA, SK; AN; JA and OE; Original Manuscript Draft: OE, AM, MA, and JA; Manuscript Revision and Approval: all authors; Supervision: MM.

**FUNDING**

Prof. MG is thankful to the IKS Based Technology Innovation Unit of DSI South Africa, for financial support (Grant contracts: DST/CON 0162/201 and DST/CON 0206/2019/2020). OE is thankful to the University of the Free State, Bloemfontein, South Africa for Incentives for Rated Researchers (2019060769); and the National Research Foundation (NRF) for Scarce Skills Postdoctoral Research Grant (UID: 132822).

**ACKNOWLEDGMENTS**

The authors are thankful for to the University of the Free State for technical support and postdoctoral support for OE,
Sunday O. Oyedemi and Omolola R. Oyenihi. The authors are also thankful for the assistance and support from the Free State Provincial Police and the Police at Port St Johns and Lusikisiki in the Eastern Cape. The authors are further thankful to Mirranda Javu, senior community liaison officer, Department of Pharmacology UFS for community engagement and negotiations on the cannabis collections. Similar appreciation goes to L R Mafura and S E Molomo both from the Ministry of Forestry, Range, Soil & Water Conservation, Mafeteng, Lesotho for the assistance with the cannabis project and cannabis wild collections.

**SUPPLEMENTARY MATERIAL**

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fphar.2021.736511/full#supplementary-material

**REFERENCES**

Al-Tannak, N. F., Novotny, L., and Alhunayan, A. (2020). Remdesivir-Bringing Hope for COVID-19 Treatment. *Sci. Pharm.* 88, 29. doi:10.3390/scipharm88020029

Alexander, S. P. H., Kelly, E., Mathie, A., Peters, J. A., Veale, E. L., Armstrong, J. F., et al. (2019). The Concise Guide to PHARMACOLOGY 2019/20: Introduction and Other Protein Targets. *Br. J. Pharmacol.* 176 (Suppl. 1), S1–S20. doi:10.1111/bjp.14747

Andersen, K. G., Rambaut, A., Lipkin, W. J., Holmes, E. C., and Garry, R. F. (2020). The Proximal Origin of SARS-CoV-2. *Nat. Med.* 26, 450–452. doi:10.1038/s41591-020-0820-9

André, C. M., Hausman, J. F., and Guerriero, G. (2016). Cannabis Sativa: The Plant of the Thousand and One Molecules. *Front. Plant. Sci.* 7, 19. doi:10.3389/fpls.2016.00119

Anil, S. M., Shalev, N., Vinayaka, A. C., Nadarajan, S., Namdar, D., Belauos, E., et al. (2020). Cannabis Compounds Have Anti-Inflammatory Activity in Lung Epithelial Cells but Pro-Inflammatory Activity in Macrophages while Increasing Phagocytosis In Vitro. *Res. Square*. doi:10.21203/rs.3.rs-9166/v1

Aso, E., and Ferrer, I. (2016). CB2 Cannabinoid Receptor as Potential Target against Alzheimer’s Disease. *Front. Neurosci.* 10, 243. doi:10.3389/fnins.2016.00243

Attia, Y. A., Alagawany, M. M., Farag, M. H., Alkhatib, F. M., Khafaga, A. F., Abdel-Moneim, A. E., et al. (2020). Phytochemicals Products and Phytochemicals as a Candidate Strategy to Improve Tolerance to Coronavirus. *Front. Vet. Sci.* 7, 573159. doi:10.3389/fvets.2020.573159

Baudoux, P., Carrat, C., Besnardeau, L., Charley, B., and Laude, H. (1998). Biovia, D. S. M. (2015).

Bhatia, R., Narang, R. K., and Rawal, R. K. (2020). A Summary of Viral Targets and Cannabis Collections. Similar appreciation goes to L R Mafura and S E Molomo both from the Ministry of Forestry, Range, Soil & Water Conservation, Mafeteng, Lesotho for the assistance with the cannabis project and cannabis wild collections.

Byrareddy, S. N., and Mohan, M. (2020). SARS-CoV-2 Induced Respiratory Distress: Can Cannabinoids Be Added to Anti-Viral Therapies to Reduce Lung Inflammation? *Brain Behav. Immun.* 87, 120–121. doi:10.1016/j.bbi.2020.04.079

Chen, Q., Liang, M., Li, Y., Guo, J., Fei, D., Wang, L., et al. (2020). Mental Health Care for Medical Staff in China during the COVID-19 Outbreak. *Lancet Psychiatry* 7, e15–e16. doi:10.1016/S2215-0366(20)30078-X

El Biali, M., Broers, B., Besson, M., and Demeules, J. (2020). Cannabinoids and COVID-19. *Med. Cannabis Cannabinoids.* 3, 1–5. doi:10.1159/000510799

Elliott, D., and Ladomery, M. (2017). *Molecular Biology of RNA*. Oxford, United Kingdom: Oxford University Press.

Erukainure, O. L., Atolani, O., Muhammad, A., Katsayal, S. B., Ebhuoma, O. O., Ibeji, C. U., et al. (2020). Targeting the Initiation and Termination Codons of SARS-CoV-2 Spike Protein as Possible Therapy Against COVID-19: The Role of Novel Harpagoside 5-O-β-D-Glucopyranoside from Clerodendrum Volubile P Beau.(Labiatae). *J. Biomol. Struct. Dyn.*, 1–14. doi:10.1080/079110220.2018.140439

Fusar-Poli, P., Crippa, J. A., Bhattacharyya, S., Borgwardt, S. J., Allen, P., Martin-Santos, R., et al. (2009). Distinct Effects of [delta]9-Tetrahydrocannabinol and Cannabidiol on Neural Activation during Emotional Processing. *Arch. Gen. Psychiatry* 66, 95–105. doi:10.1001/archgenpsychiatr.2008.519

Guzmán, M. (2003). Cannabinoids: Potential Anticancer Agents. *Nat. Rev. Cancer* 3, 745–755. doi:10.1038/nrc1188

Ho, Y., Lin, P. H., Liu, C. Y., Lee, S. P., and Chao, Y. C. (2004). Assembly of Human Severe Acute Respiratory Syndrome Coronavirus-like Particles. *Biochem. Biophys. Res. Commun.* 318, 833–838. doi:10.1016/j.bbrc.2004.04.111

Hogan, A. B., Jewell, B. L., Sherrard-Smith, E., Vesga, J. F., Watson, O. J., Whittaker, C., et al. (2020). Potential Impact of the COVID-19 Pandemic on HIV, Tuberculosis, and Malaria in Low-Income and Middle-Income Countries: A Modelling Study. *Lancet Glob. Health* 8, e1132–e1141. doi:10.1016/S2214-109X(20)30288-6

Khanna, K., Kohli, S. K., Kaur, R., Bhardwaj, A., Bhardwaj, V., Ohri, P., et al. (2021). Herbal Immune-Boosters: Substantial Warriors of Pandemic COVID-19 Battle. *Phyto medicine* 85, 153361. doi:10.1016/j.phymed.2020.153361

Kuddus, M., Ginawi, I., and AlHazimi, A. (2013). Cannabis Sativa: An Ancient Wild Edible Plant of India. *Emer. J. Food Agric.* 25, 736–745. doi:10.8755/jfag.v25i10.16400

Kumar, S., Stecher, G., Li, M., Knyaz, C., and Tamura, K. (2018). MEGA X: Molecular Evolutionary Genetics Analysis across Computing Platforms. *Mol. Biol. Evol.* 35, 1547–1549. doi:10.1093/molbev/msy096

Lee, A. (2020). Wuhan Novel Coronavirus (COVID-19): Why Global Control Is Challenging? *Public health* 179, A1. doi:10.1016/j.puhe.2020.02.001

Liu, D. X., Yuan, Q., and Liao, Y. (2007). Coronavirus Envelope Protein: a Small Severe Acute Respiratory Syndrome Coronavirus-like Particles. *Coronavirus Pseudoparticles Formed with Recombinant M and E Proteins Induce Alpha Interferon Synthesis by Leukocytes.* *J. Virol.* 81, 187435–187435. doi:10.1128/JVI.01711.18636-18643.1998

Liu, D. X., Yuan, Q., and Liao, Y. (2007). Coronavirus Pseudoparticles Formed with Recombinant M and E Proteins Induce Alpha Interferon Synthesis by Leukocytes. *J. Virol.* 81, 18636–18643. doi:10.1128/JVI.01711.18636-18643.1998

Mabou, Tagne, A., Pacchetti, B., Sodergren, M., Cosentino, M., and Marino, F. (2020). Cannabidiol for Viral Diseases: Hype or Hope? *Cannabis Cannabinoid Res.* 5, 121–131. doi:10.1089/can.2019.0060

MacIntyre, C. R. (2020). Global Spread of COVID-19 and Pandemic Potential. *Glob. Biocure* 1, 3. doi:10.31466/gbio.55

Mcbride, R., Van Zyl, M., and Fielding, B. (2014). The Coronavirus Nucleocapsid Is A Multifunctional Protein. *Viruses* 6, 2991–3018. doi:10.3390/v6082991
